title: Safety of a Trivalent Inactivated Influenza Vaccine in Health Care Workers in Kurdistan Province, Western Iran; A Longitudinal Follow-up Study.
abstract: We studied the safety of a trivalent inactivated surface antigen (split virion, inactivated) influenza vaccine, Begrivac® (Novartis Company), widely used in health care workers in Kurdistan. A longitudinal follow-up study was performed in Sanandaj city, west of Iran, recruiting 936 people. A questionnaire was completed for each participant, and all symptoms or abnormal physical findings were recorded. In part 1 of the study, the post-vaccination complaints were headache (5.3%), fever (7.9%), weakness (9.6%), chills (10.1%), sweating (10.5%), arthralgia (20.2%), and malaise (21.5%). Swelling of the injection site was seen in 267 (30.3%) participants, and pruritus of the injection site was seen in 290 (32.9%) participants. Redness and induration were also reported in 42.5% of the participants. Local reactions were mainly mild and lasted for 1-2 days. No systemic reactions were reported in the second part of the study. None of the participants experienced any inconvenience. We concluded that local adverse reactions after the trivalent inactivated split influenza vaccine, Begrivac®, in health care workers were far more common than expected. Continuous surveillance is needed to assess the potential risks and benefits of newly produced influenza vaccines.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran;
authors.forename: Jafar
authors.initials: J
authors.lastname: Soltani
authors.affiliation: Sanandaj Center for Disease Control and Prevention, Kurdistan University of Medical Sciences, Sanandaj, Iran.
authors.forename: Mohamad
authors.initials: M
authors.lastname: Jamil Amjadi
keywords: Adverse reaction; Health care worker; Influenza vaccine; Safety
references.citation: MMWR Recomm Rep. 2006 Feb 24;55(RR-2):1-16
references.pmid: 16498385
references.citation: Clin Infect Dis. 2010 Feb 15;50(4):465-7
references.pmid: 20064040
references.citation: N Engl J Med. 2001 Nov 22;345(21):1543-7
references.pmid: 11794222
references.citation: Infect Control Hosp Epidemiol. 2007 Feb;28(2):171-7
references.pmid: 17265398
references.citation: MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
references.pmid: 20689501
references.citation: J Pediatr. 2002 May;140(5):632
references.pmid: 12096708
references.citation: BMC Infect Dis. 2010 Mar 17;10:71
references.pmid: 20236548
references.citation: Infect Control Hosp Epidemiol. 2003 Nov;24(11):845-7
references.pmid: 14649773
references.citation: Vaccine. 2005 Mar 18;23(17-18):2251-5
references.pmid: 15755605
references.citation: MMWR Morb Mortal Wkly Rep. 2010 Apr 2;59(12):357-62
references.pmid: 20360669
references.citation: JAMA. 2004 Nov 24;292(20):2478-81
references.pmid: 15562126
references.citation: MMWR Recomm Rep. 2002 Feb 8;51(RR-2):1-35
references.pmid: 11848294
references.citation: Vaccine. 2008 Dec 9;26(52):6800-13
references.pmid: 18950670
references.citation: Vaccine. 2009 Feb 11;27(7):1050-4
references.pmid: 19095028
references.citation: MMWR Surveill Summ. 2003 Jan 24;52(1):1-24
references.pmid: 12825543